OOIR: Observatory of International Research

Papers

(The TQCC of Cancer Biology & Medicine is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Microsurgery vs. radiosurgery for the treatment of multiple metastases in the brain: a retrospective cohort study	161
Mitochondrial transplantation sensitizes chemotherapy to inhibit tumor development by enhancing anti-tumor immunity	88
The Warburg effect drives dedifferentiation through epigenetic reprogramming	54
Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up	49
Optimizing the cancer research landscape for the benefit of patients and society: A strategic perspective of the German Cancer Research Center (DKFZ) and its partnerships with university medical cente	48
Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II tria	43
Cancer-derived exosomal circTMEM56 enhances the efficacy of HCC radiotherapy through the miR-136-5p/STING axis	38
PD-1 inhibitors provide new opportunities in conversion therapy for stage IV gastric cancer	37
Role of the tumor microenvironment in shaping IDH-wildtype glioma plasticity, and potential therapeutic strategies	35
Associations between polymorphisms in leptin and leptin receptor genes and colorectal cancer survival	35
ACSL3 regulates breast cancer progression via lipid metabolism reprogramming and the YES1/YAP axis	34
Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer	30
Chinese Society of Clinical Oncology Non-small Cell Lung Cancer (CSCO NSCLC) guidelines in 2024: key update on the management of early and locally advanced NSCLC	27
Cancer stem cells: a target for overcoming therapeutic resistance and relapse	27
ENO1 expression and Erk phosphorylation in PDAC and their effects on tumor cell apoptosis in a hypoxic microenvironment	25
Immune checkpoint inhibitors: breakthroughs in cancer treatment	25
Effects of Helicobacter pylori eradication on the profiles of blood metabolites and their associations with the progression of gastric lesions: a	23
Cancer cell-derived migrasomes harboring ATF6 promote breast cancer brain metastasis via endoplasmic reticulum stress-mediated disruption of the blood-brain barrier	22
A machine learning model to predict efficacy of neoadjuvant therapy in breast cancer based on dynamic changes in systemic immunity	22
Advances in lung cancer screening and early detection	21
Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study	21
Nodal peripheral T-cell lymphomas in the new classification systems	21
Conceptualizing the complexity of ferroptosis to treat triple-negative breast cancer: theory-to-practice	21
Ubiquitination in osteosarcoma: unveiling the impact on cell biology and therapeutic strategies	20
Improved diagnosis of thyroid cancer aided with deep learning applied to sonographic text reports: a retrospective, multi-cohort, diagnostic study	19

Biological insights in non-small cell lung cancer	18
Facing challenges with hope: universal immune cells for hematologic malignancies	18
Intricate roles of estrogen and estrogen receptors in digestive system cancers: a systematic review	16
The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma	15
Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer	15
Elucidating the synergistic roles of CD4+ T and dendritic cells in antitumor immunity	15
Artificial intelligence-based comprehensive analysis of immune-stemness-tumor budding profile to predict survival of patients with pancreatic adenocarcinoma	15
PD-1 and LAG-3 dual blockade: emerging mechanisms and potential therapeutic prospects in cancer	15
A quick and reliable image-based AI algorithm for evaluating cellular senescence of gastric organoids	14
First-line immunotherapy for advanced non-small cell lung cancer: current progress and future prospects	14
Perspective on novel proteins encoded by circular RNAs in glioblastoma	13
Neutrophils as key regulators of tumor immunity that restrict immune checkpoint blockade in liver cancer	13
Current and future trends in whole genome sequencing in cancer	13
The role of intestinal flora on tumorigenesis, progression, and the efficacy of PD-1/PD-L1 antibodies in colorectal cancer	12
Treatment strategies for patients with HER2-positive gastric cancer	12
CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy	12
Liquid-liquid phase separation in DNA double-strand break repair	11
PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas	11
Research progress in tumor angiogenesis and drug resistance in breast cancer	10
From dichotomy to diversity: deciphering the multifaceted roles of tumor-associated macrophages in cancer progression and therapy	10
Major roles of the circadian clock in cancer	10
Deep proteome profiling promotes whole proteome characterization and drug discovery for esophageal squamous cell carcinoma	10
Anti-tumor pharmacology of natural products targeting mitosis	10
Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer	9
Drug clinical trials on high-grade gliomas: challenges and hopes	9
A causal variant rs3769823 in 2q33.1 involved in apoptosis pathway leading to a decreased risk of non-small cell lung cancer	9
The evidence and concerns about screening ultrasound for breast cancer	9
BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibi	9
Metabolic regulation of immune responses to cancer	9
Optimal immunotherapy duration in advanced NSCLC: defining the ideal treatment window	9
Comparative profiling of immune genes improves the prognoses of lower grade gliomas	8
Early detection of gastric cancer in China: progress and opportunities	8
Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification	8
The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer	8
Cancer risk in relatives of BRCA1/2 pathogenic variant carriers in a large series of unselected patients with breast cancer	8
Single-arm trials for domestic oncology drug approvals in China	8
JaponiconeA induces apoptosis of bortezomib-sensitive and -resistant myeloma cells in vitro and in vivo by targeting IKKβ	8
Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy	8
Next-generation antibody–drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer	8
IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation	8
Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer	8
N6-methyladenosine (m6A) RNA modification in tumor immunity	7
Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancer	7
MicroRNA-384 radiosensitizes human non-small cell lung cancer by impairing DNA damage response and repair signaling, which is inhibited by NF-κB	7
Development of glioblastoma organoids and their applications in personalized therapy	7
Senescent macrophages in cancer: roles in tumor progression and treatment opportunities	7
Potential treatment approaches for malignant peritoneal mesothelioma: in vivo and in vitro experimental study of natural killer cell immunotherapy	7
A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer	7
Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors	7
Epigenetic regulators as the foundation for molecular classification of colorectal cancer	7

Targeting PP2A for cancer therapeutic modulation	7
Neoantigen cancer vaccines: a new star on the horizon	7
Understanding the mechanisms underlying obesity in remodeling the breast tumor immune microenvironment: from the perspective of inflammation	7
Treatment strategies for advanced neuroendocrine neoplasms: current status and future prospects	7
Large-scale loss-of-function perturbations reveal a comprehensive epigenetic regulatory network in breast cancer	7
Erianin inhibits the proliferation of lung cancer cells by suppressing mTOR activation and disrupting pyrimidine metabolism	7
MIIP inhibits clear cell renal cell carcinoma proliferation and angiogenesis via negative modulation of the HIF-2α-CYR61 axis	7
Decoding the complexity of metastasis	7
Extracellular vesicle-mediated heterogeneous communication between cancer and the lymphatic system facilitates lymphatic metastasis	6
The inducible secreting TLR5 agonist, CBLB502, enhances the anti-tumor activity of CAR133-NK92 cells in colorectal cancer	6
Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma	6
Immunotherapy for multiple myeloma: new chances and hope	6
Erratum to Treatment strategies for patients with HER2-positive gastric cancer	6
Global, regional, and national burden of early-onset gastric cancer	6
Genomic medicine in clinical practice: national genomic medicine program in Japan	6
Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP	6
Insights into tertiary lymphoid structures in the solid tumor microenvironment: anti-tumor mechanism, functional regulation, and immunotherapeutic strategies	6
Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells	6
Mutations in Ras homolog family member A in patients with peripheral T-cell lymphoma and implications for personalized medicine	6
The evolution of cancer genomic medicine in Japan and the role of the National Cancer Center Japan	6
Hub genes associated with immune cell infiltration in breast cancer, identified through bioinformatic analyses of multiple datasets	6
Therapeutic perspectives for adult soft tissue sarcoma—updates from the 2022 ASCO annual meeting	6